Trial Profile

A phase 3 trial of Ga68-PentixaFor for the treatment of Primary Aldosteronism

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 22 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jun 2026 According to a PentixaPharm media release, the company intends to raise at least 20 million Euro gross proceeds through a capital increase by issuing up to 10,000,000 new shares. These funds will be used to finance key steps of the PANDA Phase 3 trial and support further corporate development and U.S. expansion.
09 Jun 2026 According to a PentixaPharm media release, preparations for the activation of study sites are proceeding as planned; enrollment of the first patient is expected in the second half of 2026.
09 Jun 2026 According to a PentixaPharm media release, subject to the study proceeding as planned, the US market launch is scheduled for 2030.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com